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Introduction
Esophageal variceal hemorrhage is a catastrophic
event of portal hypertension. Approximately 1-third
of cirrhotic patients experience esophageal variceal
bleeding, and the mortality rate associated with the
first episode may reach 50%.1 To prolong the survival
of cirrhotic patients with esophageal varices, the first
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episode of variceal bleeding should be effectively pre-
vented. In the past 2 decades, shunt operation and
sclerotherapy have been tried with variable success.
However, the resultant morbidities and mortalities
have led to both modalities being abandoned.1,2 On
the other hand, endoscopic variceal ligation (EVL)
has been well documented to be an effective method
in the prevention of first variceal bleeding with a rela-
tively low risk.3–5 A meta-analysis showed that EVL
was superior to β-blocker in reducing the occurrence
of first variceal bleeding.4 A combination of β-blocker
and isosorbide-5-mononitrate (ISMN) has proven to
be more effective than β-blocker alone in the preven-
tion of secondary variceal bleeding.6 Although com-
bined treatment with nonselective β-blockers and
nitrate has also been shown to be effective against first
variceal bleeding,7 to our knowledge, the comparison
between EVL and combined drug therapy in the 
prevention of first variceal bleeding has never been
reported. We, therefore, aimed to compare the effi-
cacy and safety of band ligation with drug treatment
using nadolol plus ISMN for the prophylactic pre-
vention of first bleeding in cirrhotic patients with
high-risk esophageal varices.
Methods
Patients
Between October 2002 and December 2004, patients
presenting with chronic liver disease and esophageal
varices were considered for enrollment in the trial.
Inclusion criteria were: (1) portal hypertension caused
by cirrhosis; (2) esophageal varices of moderate or
severe grade, associated with any red color signs (red
wale marking, cherry red spots, hematocystic spots); (3)
no history of hemorrhage from esophageal varices;
(4) no current treatment with β-blockers or nitrates.
The diagnosis of cirrhosis was based on liver biopsy or
clinical examination, biochemical tests and imaging
studies. Exclusion criteria were: (1) age > 75 years or
< 20 years; (2) presence of malignancy, uremia or
other serious medical illness that could reduce life
expectancy; (3) refractory ascites, hepatic encep-
halopathy or marked jaundice (serum bilirubin
> 10 mg/dL); (4) history of shunt operation, trans-
jugular intrahepatic portosystemic stent shunt or
endoscopic therapy (sclerotherapy or EVL); (5) con-
traindications to β-blockers or nitrates, e.g. asthma,
chronic obstructive airway disease, diabetes mellitus
with documented hypoglycemic episodes, congestive
heart failure, peripheral vascular disease, hypotension
(systolic blood pressure < 90 mmHg) and bradycardia
(pulse rate < 60 beats/minute); (6) allergy to either
trial medication or inability to cooperate.
Randomization
Patients eligible for the trial were randomized to
undergo band ligation (EVL group) or treatment with
nadolol plus ISMN (combination group). Randomiza-
tion was by means of opaque, sealed envelopes num-
bered according to a table of random numbers. All the
patients signed an informed consent and were followed-
up regularly. The study protocol was approved by the
ethics committee of our hospital.
Assessment
The diagnosis of cirrhosis was based on clinical and/
or imaging findings. The severity of liver disease was
assessed at presentation (Pugh modification of the Child
classification).8 Assessment of variceal size (degree)
was based on the classification of Beppu et al.9 Patients
in both groups were advised to abstain from drinking
alcohol.
Band ligation, nadolol and ISMN
Band ligation was applied after premedication with
hyoscrine-N-butyl bromide (20 mg intramuscularly).
A multiband ligator (Saeed Four-Shooter; Wilson-
Cook Medical Inc., Winston-Salem, NC, USA) and 
a videoendoscope (XQ 230; Olympus Optical Co.,
Ltd., Tokyo, Japan) were utilized. Ligations were per-
formed by 2 experienced endoscopists. During each
session of treatment, 3–4 elastic bands were placed to
ligate varices. The treatment interval was 4 weeks until
all varices were obliterated or the residual varices were
too small to be ligated. After variceal obliteration,
patients in the EVL group underwent endoscopy
every 3 months. EVL was repeated if varices recurred.
Among the patients in the combination group,
40mg of nadolol once daily (E.R. Squibb & Sons, Inc.,
Princeton, NJ, USA) was given initially and then
adjusted according to the dosage that reduced resting
pulse rate by up to 25% or 55 beats/minute. Sub-
sequently, 20 mg oral ISMN (F. Hoffmann-La Roche
Ltd., Milan, Segrate, Italy) once per day was admini-
stered concomitantly. The dose was increased over a
period of 1 week to 20 mg bid if tolerable. Compliance
was assessed by reduction of pulse rate and/or by quan-
tifying the number of tablets consumed, and inquir-
ing about how often patients did not take the drugs.
In case of side effects, nadolol was continued in patients
who could not tolerate ISMN, and ISMN was contin-
ued in patients whose side effects were nadolol-related.
Patients in both groups were advised to undergo
follow-up abdominal ultrasonography and to have
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serum α-fetoprotein and biochemical tests of liver
function at 3-month intervals.
Variceal bleeding and management
Patients suspected to have upper gastrointestinal
bleeding underwent endoscopy within 12 hours of
presentation. For patients with suspected esophageal
variceal bleeding, supportive measures included blood
transfusion, infusion of vasoconstrictor agents and ad-
ministration of lactulose and prophylactic antibiotics.
Esophageal variceal bleeding was defined as the
appearance of hematemesis or melena, documentation
of esophageal variceal bleeding at endoscopy, and a
requirement for transfusion of > 2 units of blood to
maintain stable vital signs. EVL was performed within
24 hours of esophageal variceal bleeding in both groups.
Elective EVL for prevention of recurrent bleeding
was employed for those patients with failure of pro-
phylaxis, if possible. Ligation sessions were repeated
every 3–4 weeks until the varices were obliterated for
both treatment groups.
Statistical analysis
Data were expressed as mean ± standard deviation.
Quantitative variables were compared with Student’s
t test, and qualitative variables with χ2 test and
Fisher’s exact test when appropriate. Kaplan–Meier
estimation was applied to examine the time to first
occurrence of variceal bleeding and the time to death.
In the analysis of bleeding, patients were censored 
at death or at the end of follow-up. In the analysis of
survival, patients were censored only at the end of 
follow-up. Log rank test was used to examine the
variation of bleeding episodes and survival rate. Cox
regression analysis was used to detect possible prog-
nostic variables other than treatment modality on
bleeding and survival rates. All hypothesis tests were
conducted against a 2-sided alternative, where appro-
priate. A p value < 0.05 was considered to be signifi-
cant. Analyses were performed using SPSS (SPSS Inc.,
Chicago, IL, USA). The possibility of hemorrhage from
esophageal varices after prophylactic banding ligation
varies from 0% to 15%.10 The possibility of esophageal
variceal bleeding after treatment with nadolol plus
ISMN is about 12%.6 We anticipated that if the possi-
bility of first bleeding from esophageal varices was
12% in those receiving nadolol plus ISMN, which
could be reduced to 6% in patients treated with EVL,
with a 2-tailed test to achieve a statistical power of
80% and type I error of 5%, a sample size of 352
patients in each group would be required. However,
it is impossible to enroll so many patients in a single
center. Preliminary analysis of our results showed a
similar trend. Thus, after 2 years of enrollment, we
decided to terminate this study.
Results
General characteristics
During the study period, 70 patients were screened
for possible inclusion in the trial. Of the 70 eligible
patients, 9 were excluded due to hepatocellular carci-
noma (2 patients), uremia (1), deep jaundice (2), refrac-
tory ascites (2), asthma (1) and hypotension (1).
A total of 61 patients were ultimately recruited: 30
were randomized to the EVL group and 31 to the com-
bination treatment group with nadolol plus ISMN. The
result was based on per protocol analysis (Figure 1).
The 2 groups were comparable with regard to age, gen-
der, variceal size and severity of liver disease (Table 1).
There were no significant differences in both groups.
The median duration of follow-up was 22.8 months
(range, 4.6–41.7 months) for the EVL group and 23.8
months (range, 3.9–39.6 months) for the combination
group. Three patients in the EVL group and 2 in the
combination group continued to drink alcohol. No
patients in either group were lost to follow-up.
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(Included) (n = 70)
Randomized
(n = 61)
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  carcinoma (n = 2)
Uremia (n = 1)
Deep jaundice (n = 2)
Refractory ascites (n = 2)
Asthma (n = 1)
Hypotension (n = 1)
Assigned to EVL
group (n = 30)
Assigned to combination
group (n = 31)
Lost to follow-up
(n = 0)
Lost to follow-up
(n = 0)
Analysis
(n = 30)
Analysis
(n = 31)
Figure 1. Clinical flow diagram of 77 cirrhotic patients assessed
for eligibility. A total of 16 patients were excluded due to hepato-
cellular carcinoma, uremia, deep jaundice, refractory ascites, asthma
and hypotension. A total of 61 patients were ultimately recruited,
of which 30 were randomized to the EVL group and 31 to the com-
bination group. No patients in either group were lost to follow-up.
Therefore, all 61 patients were included in the analysis. EVL =
endoscopic variceal ligation.
Variceal obliteration was achieved in 24 patients
(80%) in the EVL group. The mean number of treat-
ment sessions required for successful obliteration was
3.2 ± 0.9. The causes of failure to achieve variceal oblit-
eration included noncompliance (5 patients) and hepa-
tic failure (1 patient). In the combination group, the
median daily doses of nadolol and ISMN administered
were 40 mg and 20 mg, respectively.
There were 10 patients each in both treatment
groups with initial presence of gastric varices on enroll-
ment. Newly developed gastric varices were observed
in 2 patients (7%) in the EVL group but none in the
combination group.
Upper gastrointestinal hemorrhage
Five patients (17%) in the EVL group and 8 (26%) in the
combination group developed upper gastrointestinal
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Table 1. Characteristics of the endoscopic variceal ligation (EVL) group (n = 30) and the combination group (n = 31) at study entry*
EVL Combination p
Male/female 21/9 17/14 0.22
Age (yr) 60 ± 11 62 ± 11 0.92
Etiology of cirrhosis
Alcoholism 5 (17) 6 (19) 1.00
Hepatitis B 10 (33) 9 (29) 0.72
Hepatitis C 11 (37) 14 (45) 0.50
HBV + HCV 2 (7) 1 (3) 0.61
Cryptogenic 2 (7) 1 (3) 0.61
Albumin (g/dL) 3.3 ± 0.6 3.3 ± 0.7 0.51
Bilirubin (mg/dL) 2.0 ± 1.7 2.0 ± 1.7 0.87
Ascites present 13 (43) 9 (29) 0.25
Prothrombin time (s) 2.4 ± 1.7 1.7 ± 2.1 0.15
Encephalopathy 0 (0) 1 (3) 1.00
Child–Pugh score 7.0 ± 1.7 7.2 ± 1.8 0.41
Child–Pugh class
A 12 (40) 15 (48) 0.51
B 15 (50) 11 (35) 0.25
C 3 (10) 5 (16) 0.49
Variceal size
F2 20 (67) 19 (61) 0.66
F3 10 (33) 12 (39) 0.66
Red color signs
Mild 20 (67) 21 (68) 0.93
Moderate 9 (30) 10 (32) 0.85
Severe 1 (3) 0 (0) 0.49
Presence of gastric varices 10 (33) 10 (32) 0.93
*Data are expressed as mean ± standard deviation or n (%).
100
80
60
40
20
0
0 10 20 30 40
Pa
tie
nt
s 
fr
ee
 o
f 
EV
B
 (
%
)
p = 0.42
EVL
N + I
EVL
N + I
Months
Patients
at risk
30
31 25 15 5 0
20 16 6 1
Figure 2. Kaplan–Meier probability estimates of being free from
first bleeding from esophageal varices (EVB) in the 2 treatment
groups. EVL = endoscopic variceal ligation; N + I = nadolol +
isosorbide-5-mononitrate.
bleeding (p = 0.53). Among these patients, 3 (10%) 
in the EVL group and 6 (19%) in the combination
group bled from esophageal varices (p=0.42; Figure 2).
Among those with bleeding in the EVL group, 2
patients bled from esophageal varices before variceal
obliteration was achieved. One patient in the EVL
group bled from esophageal varices once, as well as
from gastric varices once. Bleeding from gastric
varices was also encountered once in the combina-
tion group. Thus, gastroesophageal variceal bleeding
occurred in 10% of the EVL group and 23% of 
the combination group (p = 0.29). Two patients in the
EVL group and 1 patient in the combination group
bled from peptic ulcers. Univariate analysis showed
that alcoholic etiology (risk ratio, 4.34; 95% CI, 1.16,
16.21; p = 0.029) and presence of ascites (risk ratio,
4.24; 95% CI, 1.05, 17.05; p = 0.042) were the vari-
ables significantly associated with an increased risk 
of variceal bleeding (Table 2). However, multivari-
ate analysis showed that presence of ascites was the 
only significant prognostic predictor of first variceal
bleeding (risk ratio, 4.24; 95% CI, 1.06, 17.05;
p = 0.042).
Complications
No serious adverse effect was found in either group.
Minor complications were noted in 5 patients (17%)
in the ligation group and 3 (10%) in the combination
group (p = 0.47). In the EVL group, 3 patients (10%)
experienced transient dysphagia, 1 (3%) suffered from
severe retrosternal pain that required pain control with
analgesics and 1 (3%) developed esophageal ulcer after
EVL. In the combination group, 2 patients com-
plained of headache and 1 developed hypotension.
Mortality rates
There were 8 deaths in the EVL group and 6 deaths in
the combination group (p = 0.49; Figure 3). One pa-
tient in the EVL group and 3 in the combination group
died of uncontrollable variceal bleeding (Table 3). Uni-
variate analysis revealed that serum albumin, serum
bilirubin, prothrombin time and presence of ascites
were prognostic predictors of mortality, whereas mul-
tivariate analysis showed that prothrombin time was the
only significant prognostic predictor of mortality (risk
ratio, 1.69; 95% CI, 1.27, 2.23; p < 0.001) (Table 4).
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Table 2. Univariate analysis of risk factors for esophageal variceal bleeding
Risk ratio 95% confidence interval p
Gender 1.358 0.339, 5.436 0.664
Age 0.939 0.881, 1.000 0.051
Etiology of cirrhosis
Alcoholism 4.341 1.163, 16.209 0.029
Hepatitis B 0.289 0.036, 2.311 0.242
Hepatitis C 0.604 0.150, 2.424 0.477
Albumin (g/dL) 0.904 0.339, 2.408 0.840
Bilirubin (mg/dL) 0.619 0.274, 1.396 0.248
Ascites present 4.243 1.050, 17.050 0.042*
Prothrombin time (s) 1.195 0.854, 1.674 0.299
Encephalopathy 0.723 0.887, 58.94 0.065
Treatment 1.757 0.439, 7.030 0.426
*In the definitive multivariate Cox proportional hazards regression analysis, only ascites present remained a significant risk factor.
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Figure 3. Kaplan–Meier probability estimates of survival in the 
2 treatment groups. EVL = endoscopic variceal ligation; N + I =
nadolol + isosorbide-5-mononitrate.
Discussion
Variceal bleeding is a dreadful complication of portal
hypertension, which carries a high mortality rate.1 It
is one of those complications that, if prevented, can
lead to improved survival. An analysis comparing pro-
pranolol with endoscopic injection sclerotherapy and
shunt surgery suggested that β-blocker was the only
cost-effective modality for primary prophylaxis.11
However, treatment with β-blocker does not result
in obliteration of esophageal varices. Consequently,
lifetime daily consumption of a β-blocker is necessary
to maintain the effect.12 Furthermore, the rate of
non-response may be as high as 30%.13 A significant
number of patients (45%) reported side effects with
β-blocker treatment, resulting in withdrawal from
treatment in 30% of patients.13 When propranolol is
withdrawn, the risk of variceal hemorrhage returns to
what would be expected in an untreated population.
One study also reported that some patients might
present with rebound bleeding upon abrupt cessation
of treatment with β-blocker.14 All of these situations
are drawbacks of prophylactic β-blocker therapy
against a first episode of variceal bleeding.
Because of an increase in mortality resulting from
hepatic failure, nitrate monotherapy is not regarded
as a useful regimen to prevent first variceal bleeding,
despite a similar effectiveness to β-blocker monother-
apy.15 It has been demonstrated that combination
therapy with a β-blocker and a nitrate could further
reduce hepatic venous pressure and decrease the risk
of primary variceal bleeding. Garcia-Pangan et al 
documented that hepatic venous pressure gradient
(HVPG) decreased by more than 20% of baseline
value in only 10% of patients receiving propranolol,
but in 50% of patients receiving combined therapy.16
Thus, from a clinical viewpoint, the efficacy and safety
of a combination of β-blockers plus ISMN for pri-
mary prophylaxis is still controversial,6,17,18 contrary
to the secondary prophylaxis setting in which ISMN
enhances the efficacy of a β-blocker.19 A possible
explanation for these results may depend on 2 facts:
(1) most cirrhotic patients without episodes of
variceal bleeding respond to β-blockers;20 (2) the
addition of ISMN reduces HVPG in non-responders
to β-blocker, but not in responders.21 However, the
combination of β-blockers and ISMN has never been
tried in primary prophylaxis in Chinese patients.
It is well accepted that EVL offers the same efficacy
on varices as does endoscopic injection sclerotherapy
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Table 3. Mortality in the endoscopic variceal ligation (EVL) group
(n = 30) and combination group (n = 31)
EVL Combination
n (%) n (%)
Variceal bleeding 1 (3.3) 3 (9.7)
Hepatic failure 3 (10.0) 2 (6.5)
Spontaneous bacterial 1 (3.3) 1 (3.2)
peritonitis
Hepatorenal syndrome 2 (6.7) 0 (0)
Intracranial hemorrhage 1 (3.3) 0 (0)
Total 8 (26.7) 6 (19.4)
Table 4. Multivariate analysis of risk factors for mortality
Risk ratio 95% confidence interval p
Gender 0.815 0.281, 2.366 0.707
Age 0.967 0.925, 1.011 0.137
Etiology of cirrhosis
Alcoholism 1.116 0.310, 4.011 0.867
Hepatitis B 1.145 0.357, 3.672 0.819
Hepatitis C 0.440 0.137, 1.410 0.167
Albumin (g/dL) 0.356 0.133, 0.955 0.040
Bilirubin (mg/dL) 1.249 1.042, 1.497 0.016
Ascites present 2.992 1.036, 8.642 0.043
Prothrombin time (s) 1.686 1.272, 2.234 < 0.001*
Encephalopathy 0.048 0.000, 1.293 0.759
Treatment 0.689 0.239, 1.990 0.492
*In the definitive multivariate Cox proportional hazards regression analysis, only the prothrombin time remained a significant risk factor.
but with fewer adverse effects and, thus, is the more
favored endoscopic approach to prevent first variceal
bleeding compared with sclerotherapy.22 A meta-
analysis of EVL for primary prophylaxis of esophageal
variceal bleeding demonstrated that EVL achieved a
lower risk for first variceal bleeding when compared
with β-blocker (relative risk, 0.48).4 Up to now, a
large number of studies have investigated the roles of
sclerotherapy, β-blocker and EVL in preventing first
variceal bleeding.2,6 However, there is still no con-
trolled study to compare EVL with a combination of
nitrate plus β-blocker for prevention of first variceal
bleeding. Hence, we carried out this study to investi-
gate whether nadolol plus ISMN compared to EVL
made a difference in the prevention of first variceal
bleeding in patients with cirrhosis.
The present trial compared EVL with nadolol plus
ISMN for prevention of first variceal bleeding. The
upper gastrointestinal bleeding rate was 17% in the
EVL group and 26% in the combination group
(p = 0.53), a difference that was not statistically signif-
icant. Our esophageal variceal bleeding rate was 10%
in the EVL group and 19% in the combination group
(p = 0.47). Our results were comparable with those of
previous trials that found variceal bleeding rates of 9%
to 19% in patients receiving prophylactic EVL,8,9,23–25
but slightly higher than the bleeding rate of 7.5% in
patients treated with nadolol plus ISMN.10 Because
of the small difference in reducing variceal bleeding
rate, it would require a large sample size to reach a
statistically significant difference between EVL and
combination drug therapy. EVL treatment intervals
were 4 weeks instead of weekly. Thus, the length of
time required to obliterate esophageal varices was
slightly longer in the present trial. The current trial
had fewer esophageal ulcers as compared with prior
studies. This is in disagreement with a past study by
Sarin et al,24 which reported that esophageal ulcers
were observed in 80% of patients. On the other hand,
the current trial included cirrhotic patients with gas-
tric varices. Only 1 patient in the combination group
bled from gastric varices. To our knowledge, the pres-
ence of gastric varices is not an absolute contraindi-
cation to EVL. Therefore, cirrhotic patients with
esophageal varix with/without gastric varix were ana-
lyzed for this study.
In combined medical therapy, the daily doses of
nadolol and ISMN to prevent first esophageal variceal
bleeding were lower in our patients compared to
other trials. Borroni et al reported that their final
daily dose of nadolol was 68 ± 7 mg and ISMN was
given at the initial dose of 20 mg and doubled every
3–4 days until 40 mg bid.26 A Spanish study used a
mean dose of 95 ± 56 mg/day for nadolol and the
dose of ISMN was increased to 40 mg bid.27 We pre-
sume that the varying tolerable dose of ISMN among
the different study groups may be ascribed to ethnic
differences.
Incidences of aspiration pneumonia and esophageal
bleeding after prophylactic EVL have been reported.3
Fortunately, no serious complication was found in the
current trial. Minor complications occurred with sim-
ilar frequency in both groups.
There were no significant differences between the 2
treatment groups with regard to survival rates. Patients
who underwent EVL had a lower risk of dying 
from uncontrollable variceal bleeding than those who
received combination therapy, but the difference was
not significant. Our study results are in agreement
with those of a meta-analysis of primary prophy-
laxis, which showed that survival was similar between
those treated with EVL and those treated with drug
therapy.4,10
Our preliminary results suggest that EVL has sim-
ilar effectiveness and safety to the combination of
nadolol plus ISMN in the prophylaxis against first
variceal bleeding. However, a larger, randomized
controlled trial is needed.
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